{"id":"W3188472626","doi":"10.1158/1078-0432.ccr-21-1497","title":"Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"Pharmacyclics","keywords":"Ibrutinib; Medicine; Rituximab; Waldenstrom macroglobulinemia; Internal medicine; Macroglobulinemia; Refractory (planetary science); Gastroenterology; Phases of clinical research; Progression-free survival; Neutropenia; Response Evaluation Criteria in Solid Tumors; Surgery; Clinical trial; Oncology; Lymphoma; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006392154,0.0002204115,0.001371405,0.0002687457,0.000258571,0.00003505619,0.00100598,0.0003506904,0.0009971323],"category_scores_gemma":[0.008356546,0.0001294282,0.001326192,0.004779534,0.001946997,0.00004646184,0.000995605,0.001617101,0.000007000505],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.003842167,"about_ca_system_score_gemma":0.0230976,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001234612,"about_ca_topic_score_gemma":0.0008749565,"domain_scores_codex":[0.9925668,0.001246236,0.001966799,0.0007769224,0.002600999,0.0008422645],"domain_scores_gemma":[0.990055,0.004292528,0.0003976116,0.001983518,0.003013397,0.0002580073],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5586112,0.06088312,0.04053716,0.003029558,0.02138609,0.0005568202,0.002560172,0.0004460103,0.07143686,0.001310958,0.0540902,0.1851519],"study_design_scores_gemma":[0.8062527,0.005260787,0.01150403,0.0006888447,0.003919569,0.00003035878,0.001236066,0.009136311,0.1267989,0.0001556492,0.03464723,0.0003695593],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915822,0.001334006,0.00003668772,0.003168805,0.0008076644,0.00237716,0.0002504166,0.00001302091,0.0004300159],"genre_scores_gemma":[0.9952658,0.0003497768,0.0001020334,0.000269704,0.0007067187,0.0002122158,0.00004136073,0.00003709266,0.003015337],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2476415,"threshold_uncertainty_score":0.9999965,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4036895078357418,"score_gpt":0.5643537866182178,"score_spread":0.160664278782476,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}